You are here: Industry Insights > Nucala

News List

Treatment approved for young children with severe eosinophilic asthma europeanpharmaceuticalreview
September 17, 2019
Nucala is the first biologic approved in the US for six- to 11-year-old children with severe eosinophilic asthma by the FDA.
FDA Approves Nucala (mepolizumab) for Six to 11-Year-Old Children with Severe Eosinophilic Asthma drugs
September 16, 2019
GlaxoSmithKline today announced that the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab) for use in children as young as six years old who are living with severe eosinophilic asthma.
Nucala by GSK receives EU approval for patients with severe eosinophilic asthma biospectrumasia
August 04, 2019
96% of patients in studies preferred self-administration at home over being treated in clinic
FDA OKs new administration options for GSK’s Nucala pharmatimes
June 11, 2019
GlaxoSmithKline’s Nucala (mepolizumab) has gained US Food and Drug Administration (FDA) approval for two new self-administration options, making the drug the first anti-IL5 biologic to give healthcare professionals the choice of how and where their patien
Nucala (mepolizumab) gains FDA approval for two new self-administration options worldpharmanews
June 10, 2019
Nucala (mepolizumab) gains FDA approval for two new self-administration options.
GSK gets positive opinion for Nucala self-administration from EMA pharmaceutical-technology
June 06, 2019
GlaxoSmithKline (GSK) has secured a positive recommendation from a European Medicines Agency (EMA) panel for its Nucala (mepolizumab) medication.
GSK execs change their tune as AZ, Sanofi heap pressure on respiratory hopeful Nucala fiercepharma
November 11, 2018
On the company’s third-quarter conference call last week, the British drugmaker’s pharma chief, Luke Miels, told investors the company had “very much held” AstraZeneca newcomer Fasenra “in place in Japan and Europe.”
GSK execs change their tune as AZ, Sanofi heap pressure on respiratory hopeful Nucala fiercepharma
November 11, 2018
On the company’s third-quarter conference call last week, the British drugmaker’s pharma chief, Luke Miels, told investors the company had “very much held” AstraZeneca newcomer Fasenra “in place in Japan and Europe.”
Long-term data backs safety and efficacy of GSK’s Nucala pharmatimes
November 05, 2018
GlaxoSmithKline has reported long-term safety data showing a sustained reduction in severe asthma attacks and improved asthma control ...
US regulators reject GSK’s Nucala for COPD pharmatimes
September 13, 2018
GlaxoSmithKline’s bid to expand the use of its biologic Nucala in the US to include patients with coronary pulmonary obstructive disorder (COPD) has hit a significant setback.

Previous page 1 2 3 Next page